Waters Forecasts Growth This Year After Revenue Rises in Fourth Quarter

Dow Jones

Feb 09

By Robb M. Stewart

Waters expects momentum in revenue and adjusted-earnings growth seen in the latest quarter to continue into 2026.

The maker of healthcare and science products recorded fourth-quarter net income of $225.2 million, or $3.77 a share, compared with $231.4 million, or $3.88 a year earlier. Waters' cost of sales and selling and administrative expenses were up in the latest period.

On an adjusted basis, per-share earnings rose to $4.53, just above the $4.51 mean estimate of analysts polled by FactSet.

Sales for the quarter rose 6.8% to $932.4 million from $872.7 million, where analysts expected $928.3 million for the three months. In constant currency terms, sales were up 6%.

The company said sales into the pharmaceutical market increased 8%, and 7% in constant currency. Sales into the industrial market increased 8%, but academic and government market sales decreased 2%.

For 2026, Water said it expects constant-currency revenue growth of between 5.5% and 7%. It projects revenue for the year in a $6.41 billion to $6.46 billion range.

Adjusted earnings for the year are expected to be between $14.30 and $14.50.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

February 09, 2026 07:10 ET (12:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610372896"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610372896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610372896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610372896","market":"other","top_or_hot":-1,"title":"Waters Forecasts Growth This Year After Revenue Rises in Fourth Quarter","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Waters expects momentum in revenue and adjusted-earnings growth seen in the latest quarter to continue into 2026. \n</p>\n<p>\n  The maker of healthcare and science products recorded fourth-quarter net income of $225.2 million, or $3.77 a share, compared with $231.4 million, or $3.88 a year earlier. Waters' cost of sales and selling and administrative expenses were up in the latest period. \n</p>\n<p>\n  On an adjusted basis, per-share earnings rose to $4.53, just above the $4.51 mean estimate of analysts polled by FactSet. \n</p>\n<p>\n  Sales for the quarter rose 6.8% to $932.4 million from $872.7 million, where analysts expected $928.3 million for the three months. In constant currency terms, sales were up 6%. \n</p>\n<p>\n  The company said sales into the pharmaceutical market increased 8%, and 7% in constant currency. Sales into the industrial market increased 8%, but academic and government market sales decreased 2%. \n</p>\n<p>\n  For 2026, Water said it expects constant-currency revenue growth of between 5.5% and 7%. It projects revenue for the year in a $6.41 billion to $6.46 billion range. \n</p>\n<p>\n  Adjusted earnings for the year are expected to be between $14.30 and $14.50. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 07:10 ET (12:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Waters Forecasts Growth This Year After Revenue Rises in Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWaters Forecasts Growth This Year After Revenue Rises in Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-09 20:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Waters expects momentum in revenue and adjusted-earnings growth seen in the latest quarter to continue into 2026. \n</p>\n<p>\n  The maker of healthcare and science products recorded fourth-quarter net income of $225.2 million, or $3.77 a share, compared with $231.4 million, or $3.88 a year earlier. Waters' cost of sales and selling and administrative expenses were up in the latest period. \n</p>\n<p>\n  On an adjusted basis, per-share earnings rose to $4.53, just above the $4.51 mean estimate of analysts polled by FactSet. \n</p>\n<p>\n  Sales for the quarter rose 6.8% to $932.4 million from $872.7 million, where analysts expected $928.3 million for the three months. In constant currency terms, sales were up 6%. \n</p>\n<p>\n  The company said sales into the pharmaceutical market increased 8%, and 7% in constant currency. Sales into the industrial market increased 8%, but academic and government market sales decreased 2%. \n</p>\n<p>\n  For 2026, Water said it expects constant-currency revenue growth of between 5.5% and 7%. It projects revenue for the year in a $6.41 billion to $6.46 billion range. \n</p>\n<p>\n  Adjusted earnings for the year are expected to be between $14.30 and $14.50. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 07:10 ET (12:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WAT","symbol_name":"沃特世","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610372896","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610372896","pubTimestamp":1770639000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Waters expects momentum in revenue and adjusted-earnings growth seen in the latest quarter to continue into 2026.The maker of healthcare and science products recorded fourth-quarter net income of $225.2 million, or $3.77 a share, compared with $231.4 million, or $3.88 a year earlier. Waters' cost of sales and selling and administrative expenses were up in the latest period.On an adjusted basis, per-share earnings rose to $4.53, just above the $4.51 mean estimate of analysts polled by FactSet.Sales for the quarter rose 6.8% to $932.4 million from $872.7 million, where analysts expected $928.3 million for the three months. In constant currency terms, sales were up 6%.The company said sales into the pharmaceutical market increased 8%, and 7% in constant currency. Sales into the industrial market increased 8%, but academic and government market sales decreased 2%.For 2026, Water said it expects constant-currency revenue growth of between 5.5% and 7%. It projects revenue for the year in a $","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"WAT":"沃特世"},"translate_title":"沃特世预测第四季度收入增长后今年将实现增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WAT":1.5},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  Waters expects momentum in revenue and adjusted-earnings growth seen in the latest quarter to continue into 2026. \n\n\n  The maker of healthcare and science products recorded fourth-quarter net income of $225.2 million, or $3.77 a share, compared with $231.4 million, or $3.88 a year earlier. Waters' cost of sales and selling and administrative expenses were up in the latest period. \n\n\n  On an adjusted basis, per-share earnings rose to $4.53, just above the $4.51 mean estimate of analysts polled by FactSet. \n\n\n  Sales for the quarter rose 6.8% to $932.4 million from $872.7 million, where analysts expected $928.3 million for the three months. In constant currency terms, sales were up 6%. \n\n\n  The company said sales into the pharmaceutical market increased 8%, and 7% in constant currency. Sales into the industrial market increased 8%, but academic and government market sales decreased 2%. \n\n\n  For 2026, Water said it expects constant-currency revenue growth of between 5.5% and 7%. It projects revenue for the year in a $6.41 billion to $6.46 billion range. \n\n\n  Adjusted earnings for the year are expected to be between $14.30 and $14.50. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 07:10 ET (12:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}